Biomanufacturing in gene and cell therapy

Daniel Stone¹, Xiuyang Wang^{2

3

4}, Mohamed Abou-El-Enein^{5

6

7}

Affiliations

¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
² Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
⁶ Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California and Children's Hospital of Los Angeles, Los Angeles, CA, USA.
⁷ USC/CHLA Cell Therapy Program, University of Southern California and Children's Hospital of Los Angeles, Los Angeles, CA, USA.

Editorial

Daniel Stone et al. Mol Ther Methods Clin Dev. 2024.

. 2024 May 24;32(2):101261.

doi: 10.1016/j.omtm.2024.101261. eCollection 2024 Jun 13.

Daniel Stone¹, Xiuyang Wang^{2

3

4}, Mohamed Abou-El-Enein^{5

6

7}

¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
² Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
⁶ Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California and Children's Hospital of Los Angeles, Los Angeles, CA, USA.
⁷ USC/CHLA Cell Therapy Program, University of Southern California and Children's Hospital of Los Angeles, Los Angeles, CA, USA.

No abstract available

References

1. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-produ....
1. Abou-El-Enein M., Angelis A., Appelbaum F.R., Andrews N.C., Bates S.E., Bierman A.S., Brenner M.K., Cavazzana M., Caligiuri M.A., Clevers H., et al. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol. Ther. Methods Clin. Dev. 2021;22:11–14. - PMC - PubMed
1. Abou-El-Enein M., Elsallab M., Feldman S.A., Fesnak A.D., Heslop H.E., Marks P., Till B.G., Bauer G., Savoldo B. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov. 2021;2:408–422. - PMC - PubMed
1. Mevel M., Pichard V., Bouzelha M., Alvarez-Dorta D., Lalys P.A., Provost N., Allais M., Mendes A., Landagaray E., Ducloyer J.B., et al. Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency. Mol. Ther. Methods Clin. Dev. 2024;32 - PMC - PubMed
1. Mietzsch M., Liu W., Ma K., Bennett A., Nelson A.R., Gliwa K., Chipman P., Fu X., Bechler S., McKenna R., Viner R. Production and characterization of an AAV1-VP3-only capsid: An analytical benchmark standard. Mol. Ther. Methods Clin. Dev. 2023;29:460–472. - PMC - PubMed